Tavneos(avacopan)
Tavneos (avacopan) is a small molecule pharmaceutical. Avacopan was first approved as Tavneos on 2021-10-07. It is used to treat anti-neutrophil cytoplasmic antibody-associated vasculitis in the USA. It has been approved in Europe to treat microscopic polyangiitis. It is known to target C5a anaphylatoxin chemotactic receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Tavneos
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Avacopan
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TAVNEOS | Chemocentryx | N-214487 RX | 2021-10-07 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tavneos | New Drug Application | 2025-06-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| anti-neutrophil cytoplasmic antibody-associated vasculitis | — | D056648 | I77.82 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
AVACOPAN, TAVNEOS, CHEMOCENTRYX | |||
| 2028-10-07 | ODE-377 | ||
| 2026-10-07 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Avacopan |
| INN | avacopan |
| Description | Avacopan, sold under the brand name Tavneos, is a medication used to treat anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Avacopan is a complement 5a receptor antagonist and a cytochrome P450 3A4 inhibitor.
|
| Classification | Small molecule |
| Drug class | complement receptor antagonists/complement inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 1346623-17-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989871 |
| ChEBI ID | — |
| PubChem CID | 49841217 |
| DrugBank | DB15011 |
| UNII ID | O880NM097T (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
C5AR1
C5AR1
Organism
Homo sapiens
Gene name
C5AR1
Gene synonyms
C5AR, C5R1
NCBI Gene ID
Protein name
C5a anaphylatoxin chemotactic receptor 1
Protein synonyms
C5a anaphylatoxin chemotactic receptor, C5a anaphylatoxin receptor, C5a ligand, C5a-R, C5aR, CD88, complement component 5a receptor 1
Uniprot ID
Mouse ortholog
C5ar1 (12273)
C5a anaphylatoxin chemotactic receptor 1 (Q3TZ86)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 959 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,436 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use